Create a Report
Please provide report title
Please provide location
Please provide details
Get alerts and updates for your case! Your contact information is not shown on the website.
This information is not shown on the website. We can notify you of updates, and may contact you for more information to help resolve or follow up on your issue.
Please provide email or phone
Please provide email or phone

We do not show your email or contact info

Please accept our Terms & Conditions
Add photos or video
We recommend photos and videos to help explain your report
Use camera
Select from library
Email or SMS copy of report
Enter below to get emailed a copy of your report, or sms a link to your report
Please provide email or phone
Please provide email or phone
Please accept our Terms & Conditions
Thank you for your report!
IMPORTANT - YOUR REPORT IS QUEUED - IT MAY TAKE UP TO 12 HOURS FOR YOUR REPORT TO SHOW ON OUR HOME PAGE (IF NOT OPTED AS PRIVATE)
Visit our learn pages for more helpful information or, email us: support@safelyhq.com
Goodbye! and best wishes in your recovery
Please provide location
Please provide location
Please provide report title
Please provide details
Please accept our Terms & Conditions
Get alerts and updates for your case! Your contact information is not shown on the website.

This information is not shown on the website. We can notify you of updates, and may contact you for more information to help resolve or follow up on your issue.

or
Please provide email or phone
Thank you for your report!

IMPORTANT - YOUR REPORT IS QUEUED - IT MAY TAKE UP TO 12 HOURS FOR YOUR REPORT TO SHOW ON OUR HOME PAGE (IF NOT OPTED AS PRIVATE)

If your report is poison related call 1-800-222-1222 for a free consultation with a live medical poisoning expert

Visit our learn pages for more helpful information or, email us: support@safelyhq.com

Goodbye! and best wishes in your recovery

Hyundai Power Transformers USA, Inc., 215 Folmar Pkwy, Montgomery, AL 36105, United States

Total all time reports:  1
Latest report: May 4, 2020 12:00 PM
Manufacturer employee got Coronavirus, Hyundai Power Transformers USA, Inc., 215 Folmar Pkwy, Montgomery, AL 36105, United States

Manufacturer employee got Coronavirus

May 4, 2020 12:00 PM

“Hyundai Power Transformers, USA has confirmed a case of COVID-19 among its workforce. The employee with the positive test was last on the site on April 24. Plant officials say they are suspending production for all shifts until May 4.

Source: ... See Morealabamanews.net See Less
Reported By SafelyHQ.com User

Related Reports

July 12, 2020 12:00 PM

“Three Port Authority employees recently tested positive on July 4 and one tested positive on Wednesday for Covid-19. This brings positive cases to the total number of employees to 21.

Source: pittsburgh.cbslocal.com See Less
Reported By SafelyHQ.com User

Employee test positive for Covid-19, Dairy Queen Grill & Chill, 2719 Charity St, Abbeville, LA 70510, USA

Dairy Queen Grill & Chill, 2719 Charity St, Abbeville, LA 70510, USA

July 12, 2020 12:00 PM

“An Abbeville Dairy Queen employee tests positive for COVID-19. The employee was last at work on July 3.

Source: katc.com See Less
Reported By SafelyHQ.com User

Possible Covid-19 outbreak, Duke's Seafood, 2516 Alki Ave SW, Seattle, WA 98116, USA

Duke's Seafood, 2516 Alki Ave SW, Seattle, WA 98116, USA

July 12, 2020 12:00 PM

“Six more employees at Duke's Seafood in Alki have tested positive for Covid-19 bringing the total to Seven.

Source: westseattleblog.com See Less
Reported By SafelyHQ.com User

July 12, 2020 12:00 PM

“An employee at the Willows Bar and Grill on the west side of Coldwater has been diagnosed with COVID-19. The employee las worked shifts on June 24-25 and July 2-3.

Source: wtvbam.com See Less
Reported By SafelyHQ.com User

July 12, 2020 12:00 PM

“A line cook at Lucky Pelican restaurant in the Lakewood Ranch area of Sarasota has passed away from Covid-19. His last day at work was Friday July 3.

Source: wfla.com See Less
Reported By SafelyHQ.com User

Employee test positive for Covid-19, East 55th on the Lake, 5555 N Marginal Rd, Cleveland, OH 44114, USA

East 55th on the Lake, 5555 N Marginal Rd, Cleveland, OH 44114, USA

July 12, 2020 12:00 PM

“An employee at e55 on the Lake restaurant tested positive for COVID-19. The employee last reported to work on Tuesday, July 7.

Source: fox8.com See Less
Reported By SafelyHQ.com User

July 12, 2020 12:00 PM

“Multiple employees at Hops N Drops in El Paso County have tested positive for Covid-19. The restaurant is part of an active outbreak of at least 95 people.

Source: coloradoan.com See Less
Reported By SafelyHQ.com User

July 12, 2020 12:00 PM

“Multiple employees at Mezzaluna Aspen in Pitkin County have tested positive for Covid-19. The restaurant is part of an active outbreak of at least 95 people.

Source: coloradoan.com See Less
Reported By SafelyHQ.com User

July 12, 2020 12:00 PM

“Multiple employees at the Jack in the Box in Arapahoe County have tested positive for Covid-19. The restaurant is part of an active outbreak of at least 95 people.

Source: coloradoan.com See Less
Reported By SafelyHQ.com User

July 12, 2020 12:00 PM

“A recreations counselor, a junior guards counselor and several other employees at Manasquan Recreation programs have tested positive for the virus

Source: dailyvoice.com See Less
Reported By SafelyHQ.com User

Recent Interesting Reports

Raw chicken sandwich, Wendy's, Orlando, FL 32827, United States

Wendy's, Orlando, FL 32827, United States

June 2, 2020 9:33 PM

“just received this at your MCO airport location.. i didn’t cut into this. i was served half a raw sandwich ? See Less
Reported By SafelyHQ.com User

April 29, 2020 7:00 PM

“Company name: CME America
Brand name: CMEAmerica BodyGuard
Product recalled: Infusion pumps and infusion sets
Reason of the recall: pumps may not deliver fluid at the accuracy specified in the instructions for use and infusion sets may under-deliver fluids
FDA Recall date: April 29, 2020
Recall ... See Moredetails: CME America, a wholly owned subsidiary of BD (Becton, Dickinson and Company), a leading global medical technology company, today issued the following update regarding two previously announced voluntary recalls, one related to all models of CMEAmerica BodyGuard® infusion pumps (FDA Recall Number: Z-1474-2020) and the other related to one of the device's infusion sets (FDA Recall Number: Z-1442-2020). Both previously announced recalls have now been designated as Class I recalls by the U.S. Food and Drug Administration (FDA), which means the FDA believes that there is a reasonable probability that use of the recalled product(s) will cause serious adverse health consequences or death.

CME America previously notified customers affected by each recall and provided guidance on the potential impact to device performance when the affected products were used. Today, the company has issued an updated customer letter with additional guidance and to inform customers of the decision to suspend distribution of the BodyGuard® infusion pump system and to remove all existing products from the U.S. market.

The following is a summary of each individual product recall details:

CMEAmerica BodyGuard® Infusion Pump Recall

Details On Jan. 6, 2020, the company initiated a voluntary recall to notify customers of certain scenarios where pumps may not deliver fluid at the accuracy specified in the instructions for use that could result in a slower than expected delivery of medication (under-infusion), and/or faster than expected delivery of medication (over-infusion). Results indicate that pumps may have a delivery inaccuracy of up to ~13%. To date, no reports of patient injury has been received related to this previously announced voluntary recall. CME America has assessed the potential risks associated with the issues outlined in the initial voluntary recall and determined that the BodyGuard® infusion pump may continue to be used in certain situations in accordance with the Operator's Manual and the additional mitigations outlined in the updated customer letter until the pumps have been removed from the market.

To ensure customers retain access to critical medical equipment, particularly as the COVID-19 pandemic continues to evolve in the United States, CME America will implement a phased market removal and will continue to support the following activities in order to help limit clinical disruption and maintain patient focus during the COVID-19 pandemic: Use of products in the field in accordance with the Operator's Manual and the additional mitigations outlined in the updated customer letter; Product service and repair activities at CME America and Authorized Service Depots; and Supply of infusion sets and accessories to support the infusion pumps remaining in the field.

The BodyGuard® infusion pump is designed to deliver fluids or medications into a patient's body in controlled amounts. The pump administers fluids through an infusion tubing set into a patient's vein or through other cleared routes of administration. The system is intended for patients who require maintenance medications, PCA therapy, parenteral nutritional fluids, and general IV fluid therapy in hospital and home care environments. Typical applications for the BodyGuard® infusion pumps include but are not limited to chemotherapy, pain management, TPN, enteral nutrition fluids and antibiotics.

The recall and market removal affect approximately 28,400 devices, including all models of BodyGuard® infusion pumps listed below. These devices are primarily used in outpatient settings.
- BodyGuard 121
- BodyGuard 323
- BodyGuard 545*
- BodyGuard 575*
- BodyGuard 545 ColorVision
- BodyGuard 575 ColorVision
- CMExpress

*Note: These two pump models were inadvertently left out of the initial customer notification

CMEAmerica BodyGuard® Microset Infusion Set Recall

Details On Sept. 16, 2019, the company initiated a voluntary recall to notify customers that certain lots of BodyGuard® Microset infusion sets, when used with the BodyGuard® infusion pump, may under-deliver fluids up to 50% at the highest flow rates. At the time of the recall, CME America informed customers in the recall announcement to discard all remaining inventory of the infusion sets (Catalog #A120-003XYVA) and committed to reimbursing impacted customers. To date, no reports of patient injury has been received related to this previously announced voluntary recall. CME America immediately stopped shipments of the affected infusion sets. This FDA classification does not change the previous guidance provided in the company's September recall announcement to customers. Affected products include:

CMEAmerica BodyGuard® Microset, Catalog #A120-003XYVA.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

Check the full recall details on fda.gov

Source: FDA
See Less
Reported By SafelyHQ.com User

April 12, 2020 12:00 PM

“Details:
An employee at the Schnucks in Ladue has tested positive for COVID-19. The employee had not been to work since April 2 and is now quarantined at home.

The store is now open to customers after the deep cleaning.

Report: 3/27/2020
Source: ... See More>kmov.com See Less
Reported By SafelyHQ.com User

July 6, 2020 12:53 PM

“Order from Walmart delivers. SOUTHERN HENS (frozen chicken.)
When thawed and removing giblets, to my horror, there was a brow ... See Morele="Product: Egg">egg inside the hen!!!! The inside of the egg had dispersed but the shell was partly attached to itself. Contacted company and they told me that they had never heard of anything like this before... I have pics!!!!! Reported to Walmart and they are STILL SELLING THEM!!!!!
I would also like to name all the agencies in MS That I contacted and they kept telling me they were not responsible?!? Six Mississippi agencies where this plant is located...Yet Walmart keeps selling them!!
I called the Board of Health in Mississippi, I called the FDA, the USDA, I called Southern Hen and spoke to a person. There was no action taken, none! nobody cares that there was a frickin egg inside of a frozen hen See Less
Reported By SafelyHQ.com User

May 20, 2020 10:00 PM

“Company name: Biota Biosciences, LLC
Brand name: Biota Biosciences
Product recalled: Cannabidiol (CBD) Complex, Curcumin Complex, Cannabidiol + Curcumin
Reason of the recall: Unapproved new drug
FDA Recall date: May 20, 2020
Recall details: Biota Biosciences is voluntarily recalling the followi ... See Moreng lots in the table below of Cannabidiol (CBD) Complex, Curcumin Complex, and Cannabidiol + Curcumin Injectables to the customer level. These injectable products are being recalled because they were marketed without FDA approval. The products claims on our website make these products unapproved new drugs. Further, the products are misbranded because the labeling fails to bear adequate directions for use.

- Product Name: Cannabidiol(CBD)Complex / Strength(mg): 40 / Multiple Dose Vial Size: 10 mL / Lot: 2H071219P / Expiration: 07/12/2021

- Product Name: Cannabidiol(CBD)Complex / Strength(mg): 500 / Multiple Dose Vial Size: 10 mL / Lot: 10102019P / Expiration: 10/10/2021

- Product Name: Curcumin Complex / Strength(mg): 40 / Multiple Dose Vial Size: 10 mL / Lot: 2H071219CCD / Expiration: 07/12/2021

- Product Name: Curcumin Complex / Strength(mg): 500 / Multiple Dose Vial Size: 10 mL / Lot: 0712019CCD / Expiration: 07/12/2021

- Product Name: Cannabidiol + Curcumin / Strength(mg): 500 / Multiple Dose Vial Size: 10 mL / Lot: 10102019PC / Expiration: 10/10/2021

Risk Statement: Unapproved new drugs injected into the bloodstream for which safety and efficacy have not been established could pose a serious risk of harm to users because they bypass many of the body’s natural defenses against toxic ingredients, toxins, or dangerous organisms that can lead to serious and life-threatening conditions such as septicemia or sepsis. Biota Biosciences has not received any reports of adverse events related to this recall.

Risk Statement: Unapproved new drugs injected into the bloodstream for which safety and efficacy have not been established could pose a serious risk of harm to users because they bypass many of the body’s natural defenses against toxic ingredients, toxins, or dangerous organisms that can lead to serious and life-threatening conditions such as septicemia or sepsis. Biota Biosciences has not received any reports of adverse events related to this recall.

Cannabidiol (CBD) Complex was marketed to suppress pain and aid in the detoxification processes as a promising therapeutic for a wide array of disorders such as epilepsy, including many challenging neuropathy conditions. Curcumin Complex was marketed as a potent anti-inflammatory and antioxidant that may also help improve symptoms of depression and arthritis. Cannabidiol + Curcumin was marketed as a more efficient therapeutic effect. The product was sold to certified practitioners who further administer to customers. The product is packaged in 10 mL sterile vials. Products were distributed Nationwide in the USA and one consignee in New Zealand.

Water Soluble 40mg/10m products can be identified by the labels attached.

Water Soluble 500mg/10m products can be identified by the labels attached.

Check the full recall details on fda.gov

Source: FDA
See Less
Reported By SafelyHQ.com User

May 26, 2020 9:32 AM

“They're trying to kill me serving me raw chicken See Less
Reported By SafelyHQ.com User

March 19, 2020 2:35 PM

“Lindt & Sprüngli (USA) Inc. of Stratham, New Hampshire, is issuing a voluntary recall of one lot of its Lindt Excellence 85% Cocoa chocolate bars due to the bars being wrapped in the wrong packagi ... See Moreng. The bars are labeled as Excellence 85% Cocoa, but contain Lindt Excellence Dark Caramel Sea Salt bars. Therefore, this product does not contain accurate information about allergens.

Consumers who have a food allergy or have any sensitivity to milk or soy should not consume the product as it could result in a serious or life-threatening allergic reaction.

The recalled Lindt Excellence 85% Cocoa chocolate bars are labeled with Lot Code L5539, a Best Before date of 11-30-2020, and UPC of 3746601645.

For more information go here: fda.gov

Source: FDA
See Less
Reported By SafelyHQ.com User

May 26, 2020 9:34 PM

“Wifey wants to thank you for the raw chicken sandwich and upcoming bout of diarrhea. PukeCity See Less
Reported By SafelyHQ.com User

June 5, 2020 4:00 PM

“Company name: Teva Pharmaceuticals USA Inc.
Brand name: Actavis
Product recalled: Metformin Hydrochloride Extended-Release Tablets, USP 500mg and 750mg
Reason of the recall: Due to detection of N-Nitrosodimethylamine (NDMA)
FDA Recall date: June 05, 2020
Recall details: Teva Pharmaceuticals U ... See MoreSA, Inc. is voluntarily recalling fourteen (14) lots of Metformin Hydrochloride Extended-Release Tablets, USP 500 mg and 750 mg, 100 and 1000 count bottles, in the United States to the consumer-level due to the detection of N-Nitrosodimethylamine (NDMA) levels in excess of the Acceptable Daily Intake Limit (ADI). NDMA is classified as a probable human carcinogen (a substance that could cause cancer) based on results from laboratory tests. NDMA is a known environmental contaminant and found in water and foods, including meats, dairy products, and vegetables. Metformin Hydrochloride is indicated as an adjunct to diet and exercise to improve blood glucose control in adults with type 2 diabetes mellitus.

The lots being recalled are packaged under the Actavis Pharma, Inc. label and are contained in the table below. They were distributed nationwide in the USA as retail bottles of 100 tablets and 1000 tablets to Teva’s direct customers between January 8, 2019 and May 27, 2020. The affected Metformin Hydrochloride Extended-Release Tablets, USP 500 mg and 750 mg, being recalled are described as:

- Metformin Hydrochloride Extended-Release Tablets, USP 500 mg, white to off-white capsule shaped tablets, debossed with an Andrx logo with “571”on one side and “500” on the opposite side.

- Metformin Hydrochloride Extended-Release Tablets, USP 750 mg, light yellow capsule shaped tablets, debossed with an Andrx logo with “577” on one side and “750” on the opposite side.

- NDC: 62037-571-01/ Product Description Metformin Hydrochloride Extended-Release Tablets, USP 500 mg 100 Count/ Lot Number: 1329548A/ Expiration: 06/2020

- NDC: 62037-571-01/ Product Description: Metformin Hydrochloride Extended-Release Tablets, USP 500 mg 100 Count/ Lot Number: 1338302M/ Expiration: 10/2020

- NDC: 62037-571-01/ Product Description: Metformin Hydrochloride Extended-Release Tablets, USP 500 mg 100 Count/ Lot Number: 1348968M/ Expiration: 10/2020

- NDC: 62037-571-01/ Product Description: Metformin Hydrochloride Extended-Release Tablets, USP 500 mg 100 Count/ Lot Number: 1348969M/ Expiration: 11/2020

- NDC: 62037-571-01/ Product Description: Metformin Hydrochloride Extended-Release Tablets, USP 500 mg 100 Count/ Lot Number: 1348970M/ Expiration: 10/2020

- NDC: 62037-571-01/ Product Description: Metformin Hydrochloride Extended-Release Tablets, USP 500 mg 100 Count/ Lot Number: 1376339M/ Expiration: 09/2021

- NDC: 62037-571-10/ Product Description: Metformin Hydrochloride Extended-Release Tablets, USP 500 mg 1000 Count/ Lot Number: 1323460M/ Expiration: 06/2020

- NDC: 62037-571-10/ Product Description: Metformin Hydrochloride Extended-Release Tablets, USP 500 mg 1000 Count/ Lot Number: 1330919M/ Expiration: 06/2020

- NDC: 62037-571-10/ Product Description: Metformin Hydrochloride Extended-Release Tablets, USP 500 mg 1000 Count/ Lot Number: 1338300A/ Expiration: 10/2020

- NDC: 62037-571-10/ Product Description: Metformin Hydrochloride Extended-Release Tablets, USP 500 mg 1000 Count/ Lot Number: 1341135M/ Expiration: 12/2020

- NDC: 62037-571-10/ Product Description: Metformin Hydrochloride Extended-Release Tablets, USP 500 mg 1000 Count/ Lot Number: 1391828M/ Expiration: 11/2021

- NDC: 62037-577-01/ Product Description: Metformin Hydrochloride Extended-Release Tablets, USP 750 mg 100 Count/ Lot Number: 1333338M/ Expiration: 08/2020

- NDC: 62037-577-01/ Product Description: Metformin Hydrochloride Extended-Release Tablets, USP 750 mg 100 Count/ Lot Number: 1333339A/ Expiration: 08/2020

- NDC: 62037-577-10/ Product Description: Metformin Hydrochloride Extended-Release Tablets, USP 750 mg 1000 Count/ Lot Number: 1354471A/ Expiration: 02/2021

Teva is notifying its distributors and customers affected by this recall via FedEx overnight mailing. Patients taking Metformin Hydrochloride Extended-Release Tablets, USP 500 mg and 750 mg, are advised to continue taking their medication and contact their pharmacist, physician, or medical provider for advice regarding an alternative treatment. According to the US Food & Drug Administration, It could be dangerous for patients with this serious condition to stop taking their metformin without first talking to their health care professionals.

Check the full recall details on fda.gov

Source: FDA
See Less
Reported By SafelyHQ.com User

July 13, 2020 5:32 AM

“I am so disgusted. Raw chicken 🥴🥴🥴🥴 See Less
Reported By SafelyHQ.com User